Cargando…
Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework
Human papillomavirus (HPV) assays used in cervical cancer screening should be clinically validated according to international criteria. OncoPredict HPV® Screening (SCR) is a partial genotyping multiplex real‐time PCR assay targeting E6/E7 genes of 13 high‐risk (hr) HPVs. OncoPredict HPV® SCR (index...
Autores principales: | Dhillon, Sharonjit K., Cocuzza, Clementina E., Chung, Pui Yan Jenny, Martinelli, Marianna, Giubbi, Chiara, Njoku, Ruth C., Bhatia, Ramya, Cuschieri, Kate, Arbyn, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107715/ https://www.ncbi.nlm.nih.gov/pubmed/36541733 http://dx.doi.org/10.1002/jmv.28417 |
Ejemplares similares
-
Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework
por: Dhillon, Sharonjit K., et al.
Publicado: (2021) -
Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework
por: Bhatia, Ramya, et al.
Publicado: (2023) -
Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel
por: Polman, N. J., et al.
Publicado: (2017) -
Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT Framework
por: Xu, Lan, et al.
Publicado: (2018) -
VALCOR: a protocol for the validation of SARS-corona virus-2 assays
por: Arbyn, Marc, et al.
Publicado: (2022)